ПОВОЛЖСКИЙ ОНКОЛОГИЧЕСКИЙ ВЕСТНИК 1 ( 28 )’ 2017
23 . Ljungberg B . et al . Tumour vascular endothelial growth factor ( VEGF ) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma // Urological research . — 2003 . — Vol . 31 , № 5 . — P . 335-340 .
24 . Maroto P ., Rini B . Molecular biomarkers in advanced renal cell carcinoma // Clinical Cancer Research . — 2014 . — Vol . 20 , № 8 . — P . 2060-2071 .
25 . Moch H . An overview of renal cell cancer : pathology and genetics // Seminars in cancer biology . — Academic Press , 2013 . — Vol . 23 , № 1 . — P . 3-9 .
26 . Moch H . et al . Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma // Cancer . — 2000 . — Vol . 89 , № 3 . — P . 604-614 .
27 . Motzer R . J . et al . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma // New England Journal of Medicine . — 2007 . — Vol . 356 , № 2 . — P . 115-124 .
28 . Nisman B . et al . Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy // Urology . — 2010 . — Vol . 76 , № 2 . — P . 513 . e1-513 . e6 .
29 . Rini B . I . et al . Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumabrefractory metastatic renal cell carcinoma // Journal of Clinical Oncology . — 2008 . — Vol . 26 , № 22 . — P . 3743-3748 .
30 . Sachdeva K . et al . Renal Cell Carcinoma [ Электронный ресурс ]. URL : http :// emedicine . medscape . com / article / 281340-overview . Дата обращения : 02.08.16
31 . Shinagare A . B . et al . Radiogenomics of clear cell renal cell carcinoma : preliminary findings of The Cancer
Genome Atlas – Renal Cell Carcinoma ( TCGA – RCC ) Imaging Research Group // Abdominal imaging . — 2015 . — Vol . 40 , № 6 . — P . 1684-1692 .
32 . Teloken P . E . et al . Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma // The Journal of urology . — 2009 . — Vol . 182 , № 5 . — P . 2132-2136 .
33 . Varga Z . et al . Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma : a suitable tumor marker ? // Urological research . — 2002 . — Vol . 30 , № 2 . — P . 122-125 .
34 . von Teichman A . et al . VHL mutations and dysregulation of pVHL-and PTEN-controlled pathways in multilocular cystic renal cell carcinoma // Modern Pathology . — 2011 . — Vol . 24 , № 4 . — P . 571-578 .
35 . Wader J . V . et al . Chromophobe Renal Cell Carcinoma // Online Journal of Health and Allied Sciences . — 2013 . — Vol . 12 , № 1 ( 15 ).
36 . Ward C . S . et al . Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy // Cancer research . — 2010 . — Vol . 70 , № 4 . — P . 1296-1305 .
37 . Zurita A . J . et al . A cytokine and angiogenic factor ( CAF ) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma // Annals of oncology . — 2011 . — С . mdr047 .
38 . Zurita-Saavedra A . et al . Multivariate analysis of cytokines and angiogenic factors ( cafs ) and established prognostic parameters in metastatic renal cell carcinoma ( mrcc ) patients ( pts ) receiving pazopanib or placebo // Annals of oncology . — Great Clarendon st , Oxford ox2 6dp , England : Oxford Univ Press , 2012 . — Vol . 23 . — P . 261-261 .
С . Ю . Иливанов и соавт . Рациональное использование биомаркеров в диагностике рака почки в клинической практике 79